It is classified as a moderate-penetrance gene [9, 10] has been demonstrated that high ATM protein tumor expression correlates with adverse prognosis in ovarian cancers [11], while ATM deficiency appears to be associated with better prognosis in several cancer types, especially after Poly ADP-Ribose polymerase inhibitors (PARPi) treatment [12]. This evidence concerns the gene ATM and ovarian carcinoma.